These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31717777)

  • 1. Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90).
    Mak OW; Chand R; Reynisson J; Leung IKH
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β.
    Yim KH; Prince TL; Qu S; Bai F; Jennings PA; Onuchic JN; Theodorakis EA; Neckers L
    Proc Natl Acad Sci U S A; 2016 Aug; 113(33):E4801-9. PubMed ID: 27466407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
    Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
    PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.
    Millson SH; Truman AW; Rácz A; Hu B; Panaretou B; Nuttall J; Mollapour M; Söti C; Piper PW
    FEBS J; 2007 Sep; 274(17):4453-63. PubMed ID: 17681020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Middle domain of human Hsp90 isoforms differentially binds Aha1 in human cells and alters Hsp90 activity in yeast.
    Synoradzki K; Bieganowski P
    Biochim Biophys Acta; 2015 Feb; 1853(2):445-52. PubMed ID: 25486457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Inhibition of the Hsp90α Isoform.
    Mishra SJ; Khandelwal A; Banerjee M; Balch M; Peng S; Davis RE; Merfeld T; Munthali V; Deng J; Matts RL; Blagg BSJ
    Angew Chem Int Ed Engl; 2021 May; 60(19):10547-10551. PubMed ID: 33621416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytosolic Hsp90 Isoform-Specific Functions and Clinical Significance.
    Maiti S; Picard D
    Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Design, Synthesis, and Biological Evaluation of Hsp90β-Selective Inhibitors.
    Chaudhury S; Narasimharao Meka P; Banerjee M; Kent CN; Blagg BSJ
    Chemistry; 2021 Oct; 27(59):14747-14764. PubMed ID: 34449940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of the middle domains stabilizes Hsp90α dimer in a closed conformation with high affinity for p23.
    Synoradzki K; Miszta P; Kazlauskas E; Mickevičiūtė A; Michailovienė V; Matulis D; Filipek S; Bieganowski P
    Biol Chem; 2018 Mar; 399(4):337-345. PubMed ID: 29337688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities.
    Dernovšek J; Tomašič T
    Pharmacol Ther; 2023 May; 245():108396. PubMed ID: 37001734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue.
    McDowell CL; Bryan Sutton R; Obermann WM
    Int J Biol Macromol; 2009 Oct; 45(3):310-4. PubMed ID: 19576239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GCUNC45 is the first Hsp90 co-chaperone to show alpha/beta isoform specificity.
    Chadli A; Felts SJ; Toft DO
    J Biol Chem; 2008 Apr; 283(15):9509-12. PubMed ID: 18285346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation, migration, and resistance to oxidative and thermal stresses of HT1080 cells with knocked out genes encoding Hsp90α and Hsp90β.
    Petrenko V; Vrublevskaya V; Bystrova M; Masulis I; Kopylova E; Skarga Y; Zhmurina M; Morenkov O
    Biochem Biophys Res Commun; 2023 Sep; 674():62-68. PubMed ID: 37406487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.
    Khandelwal A; Kent CN; Balch M; Peng S; Mishra SJ; Deng J; Day VW; Liu W; Subramanian C; Cohen M; Holzbeierlein JM; Matts R; Blagg BSJ
    Nat Commun; 2018 Jan; 9(1):425. PubMed ID: 29382832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking.
    Peterson LB; Eskew JD; Vielhauer GA; Blagg BS
    Mol Pharm; 2012 Jun; 9(6):1841-6. PubMed ID: 22554505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta.
    Millson SH; Prodromou C; Piper PW
    Biochem Pharmacol; 2010 Jun; 79(11):1581-8. PubMed ID: 20138026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of heat shock protein 90 isoforms in small cell lung cancer.
    Lee JH; Kang KW; Kim JE; Hwang SW; Park JH; Kim SH; Ji JH; Kim TG; Nam HY; Roh MS; Lee EH; Park MI; Kim MS; Lee HW
    Int J Clin Exp Pathol; 2015; 8(8):9487-93. PubMed ID: 26464709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells.
    Houlihan JL; Metzler JJ; Blum JS
    J Immunol; 2009 Jun; 182(12):7451-8. PubMed ID: 19494268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs.
    Phillips JJ; Yao ZP; Zhang W; McLaughlin S; Laue ED; Robinson CV; Jackson SE
    J Mol Biol; 2007 Oct; 372(5):1189-203. PubMed ID: 17764690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.
    Ernst JT; Liu M; Zuccola H; Neubert T; Beaumont K; Turnbull A; Kallel A; Vought B; Stamos D
    Bioorg Med Chem Lett; 2014 Jan; 24(1):204-8. PubMed ID: 24332488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.